OncoSeek

OncoSeek combines seven protein tumour markers with age and sex. In the pooled validation (Shen et al., npj Precision Oncology 2025; 15,122 participants, 3,029 with cancer, seven centres in three countries) it had an area under the curve of 0.829, 58.4% sensitivity, 92.0% specificity and 70.6% tissue-of-origin accuracy in true positives, across 14 cancer types with sensitivities of 38.9% to 83.3%. The first study (Luan et al., eClinicalMedicine 2023; 7,565 participants plus a Johns Hopkins validation cohort) reported 51.7% sensitivity and 92.9% specificity.

At 92% specificity about 8 in 100 people without cancer test positive, far more than with DNA-based tests run at 98 to 99.5%, so in a screening population most positives would not be cancer. SeekIn's website claims 14 high-mortality cancers with the same 58.4% and 92.0% figures; CE marking was reported in September 2022 for 12 cancers. No NMPA or FDA status, price or registered trial was found.